Can you take GHK (Glycine-Histidine-Lysine Tripeptide) and Thymosin Beta-4 together?

There is no specific, well-documented interaction rule for combining GHK (Glycine-Histidine-Lysine Tripeptide) and Thymosin Beta-4 in the aggregated research reviewed. Combining peptides should only be considered under professional supervision. This is not medical advice.

Which is better researched, GHK (Glycine-Histidine-Lysine Tripeptide) or Thymosin Beta-4?

GHK (Glycine-Histidine-Lysine Tripeptide) is currently research-stage and Thymosin Beta-4 is investigational (in trials). "Better researched" depends on your research goal — review each profile's cited sources.

Healing & Recovery · Comparison

GHK (Glycine-Histidine-Lysine Tripeptide) vs Thymosin Beta-4

Q: What is the difference between GHK (Glycine-Histidine-Lysine Tripeptide) and Thymosin Beta-4?

GHK (Glycine-Histidine-Lysine Tripeptide): The free tripeptide component of GHK-Cu before copper complexation. GHK naturally occurs in human plasma, saliva, and urine and promotes wound healing, collagen synthesis, and anti-inflammatory activity. While it readily chelates copper to form GHK-Cu in vivo, research distinguishes the independent effects of free GHK from the copper-complexed form on gene expression and tissue remodeling. Thymosin Beta-4: Thymosin Beta-4 (TB4) is the full-length 43-amino acid peptide produced naturally in high concentrations in platelets, wound fluid, and regenerating tissue. It is the parent molecule from which the popular TB-500 research peptide (the 17-23 fragment Ac-LKKTETQ) is derived. TB4 promotes actin polymerization, accelerates wound healing, reduces inflammation, and supports cardiac and neurological repair in preclinical models. Both are in the Healing & Recovery category but differ in mechanism, dosing, and research evidence — see the full comparison.

A neutral, side-by-side comparison of two healing & recovery peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.

GHK (Glycine-Histidine-Lysine Tripeptide)

Research-stage

The free tripeptide component of GHK-Cu before copper complexation. GHK naturally occurs in human plasma, saliva, and urine and promotes wound healing, collagen synthesis, and anti-inflammatory activity. While it readily chelates copper to form GHK-Cu in vivo, research distinguishes the independent effects of free GHK from the copper-complexed form on gene expression and tissue remodeling.

Full profile

Thymosin Beta-4

Investigational (in trials)

Thymosin Beta-4 (TB4) is the full-length 43-amino acid peptide produced naturally in high concentrations in platelets, wound fluid, and regenerating tissue. It is the parent molecule from which the popular TB-500 research peptide (the 17-23 fragment Ac-LKKTETQ) is derived. TB4 promotes actin polymerization, accelerates wound healing, reduces inflammation, and supports cardiac and neurological repair in preclinical models.

Full profile

	GHK (Glycine-Histidine-Lysine Tripeptide)	Thymosin Beta-4
Category	Healing & Recovery	Healing & Recovery
Also known as	GHK tripeptide, Gly-His-Lys, copper chelating tripeptide, GHK free tripeptide	TB4, Tβ4, Tβ4 full-length
Evidence	Research-stage	Investigational (in trials)
Dosing range	0.5mg–2mg mg, Daily or every other day (topical or SC)	500mcg–2000mcg mcg, 2–3x weekly
Administration	Subcutaneous injection, Topical (cream/serum)	Subcutaneous injection, Intramuscular injection, Intravenous (clinical studies only)
Key side effects	Minimal reported side effects, Mild injection site irritation, Rare topical sensitization, No significant systemic effects at research doses	Injection site discomfort (mild), Transient fatigue post-injection, Headache (uncommon), Theoretically may accelerate growth of pre-existing malignant tumors (promotes angiogenesis and cell migration — use with caution)
Cited sources	2 references	3 references

Key differences

Evidence level differs: GHK (Glycine-Histidine-Lysine Tripeptide) is research-stage, while Thymosin Beta-4 is investigational (in trials).
Administration: GHK (Glycine-Histidine-Lysine Tripeptide) — Subcutaneous injection, Topical (cream/serum); Thymosin Beta-4 — Subcutaneous injection, Intramuscular injection, Intravenous (clinical studies only).
Dosing units differ: GHK (Glycine-Histidine-Lysine Tripeptide) is dosed in mg, Thymosin Beta-4 in mcg — they operate at different scales.
Frequency: GHK (Glycine-Histidine-Lysine Tripeptide) is typically Daily or every other day (topical or SC); Thymosin Beta-4 is 2–3x weekly.
Research depth: this profile cites 2 sources for GHK (Glycine-Histidine-Lysine Tripeptide) vs 3 for Thymosin Beta-4.

How each works

GHK (Glycine-Histidine-Lysine Tripeptide)

Free GHK directly upregulates collagen, elastin, and laminin synthesis in fibroblasts through TGF-β pathway activation and metalloproteinase modulation. Loren Pickart's decades of research identified GHK as a potent tissue remodeling signal whose plasma concentrations decline with age. At physiologic concentrations, GHK resets approximately 31% of dysregulated gene expression associated with aging back toward a younger phenotype.

Thymosin Beta-4

TB4's primary mechanism involves sequestering G-actin monomers (via its LKKTET actin-binding domain) to regulate actin cytoskeleton dynamics — critical for cell migration, wound closure, and tissue remodeling. Clinical trials have evaluated TB4 for corneal wound healing (Phase 2), pressure ulcers, and cardiac repair after MI. The FACT trial investigated TB4 in patients with ischemic heart failure, showing trends toward improved cardiac function. Anti-inflammatory effects are mediated partly through NF-κB pathway downregulation.

Read the full GHK (Glycine-Histidine-Lysine Tripeptide) profile Read the full Thymosin Beta-4 profile

This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.